Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz3. fázis

A study to test trimodulin in adult hospitalized patients with severe pneumonia

A legfontosabb adatok

Ki végzi
Biotest GmbH & Co. KGaA
Hol
Ausztria, Belgium, Csehország, Franciaország, Írország, Magyarország, Németország, Románia és Spanyolország56 helyszín, 9 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
3. fázis
Résztvevők
275 fő, tervezett
Kezdés
2023. jún. 7.
Várható befejezés
2028. dec. 29.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2026. július 20.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 34 feltétel megnézéseKevesebb

Ki vehet részt

  • Written informed consent obtained from subject or legally acceptable/authorized representative (LAR)
  • Hospitalized, adult (≥ 18 years of age) subject (any gender)
  • C-reactive protein (CRP) ≥ 70 mg/L up to 1 calendar day prior to start of treatment with IMP
  • Diagnosis of active community-acquired pneumonia (CAP) before hospital-admission or within 48 hours after admission
  • Radiological (or other imaging technology) evidence consistent with active pneumonia must be available from routine SoC
  • Acute respiratory failure requiring IMV, defining sCAP (Appendix 9: sCAP Diagnostic Criteria According to the ATS/IDSA Guideline)
  • Treatment with IMP must be started between 1 and 24 hours after initiation of IMV
  • Subject must receive SoC treatment for sCAP according to applicable regional and global sCAP guidelines

Ki nem vehet részt

  • Selective IgA deficiency with known antibodies to IgA
  • Treatment with > 1 g/kg body weight of polyvalent immunoglobulin preparation in total during the last 21 days before start of IMP treatment
  • Treatment with fluoroquinolone preparations, during the last 2 days before start of IMP treatment
  • Hematopoietic stem cell transplantation within 1 year, or previous lung transplantation
  • Treatment with investigational medications procedures not according to SoC of the trial site , due to participation in another interventional clinical tria within 30 days before start of IMP treatment or previous IMP treatment with IMP in this clinical trial
  • Subjects discharged from hospital within the previous 14 days
  • Thromboembolic events (TEEs) caused by other reasons than the current sCAP (e.g., cerebrovascular accidents, transient ischemic attack, myocardial infarction, pulmonary embolism, and deep vein thrombosis) within 3 months before start of IMP treatment.. unless the risk for further TEEs can be adequately managed with standard prophylaxis or treatment
  • Pre-existing severe lung diseases concomitant to current sCAP (e.g., subjects with active tuberculosis, or active lung cancer)
  • Life expectancy of less than 90 days, according to the investigator’s clinical judgment, because of medical conditions related neither to sCAP nor to sCAP-associated septic conditions
  • Pre-existing hemolytic disease
  • End-stage renal disease (ESRD) or known primary focal segmental glomerulosclerosis (FSGS)
  • Pre-existing decompensated heart failure (New York Heart Association class III–IV)
  • Pre-existing severe hepatic cirrhosis, (Child Pugh score ≥ 10 points), or severe hepatic impairment (Child Pugh score ≥ 10 points), or hepatocellular carcinoma
  • Known intolerance to proteins of human origin or known allergic reactions to any of the components of trimodulin / placebo
  • Severe neutropenia (neutrophil count <500/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Thrombocytopenia (platelet count <30,000/mm³) per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Hemoglobin (Hb) < 7 g/dL hours per most recent test performed up to 1 calendar day prior to start of IMP treatment
  • Severe renal impairment, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² per most recent test performed up to 1 calendar day prior to start of IMP treatment (details in Appendix 2: Estimated Glomerular Filtration Rate).*), unless the subject is already on dialysis or continuous replacement therapy
  • For an incapacitated subject: any indication that the subject’s presumed will would be against inclusion in the trial
  • Pregnant or lactating women
  • Morbid obesity with high body mass index (BMI) ≥ 40 kg/m2, or malnutrition with low BMI < 16 kg/m2
  • Employee or direct relative of an employee of the CRO, or the trial site, if employee is directly involved in the trial or otherwise in a dependent relationship with the site staff
  • Persons, subject to legal protection measures, if applicable according to local laws
  • Subjects of childbearing potential not willing to use reliable contraceptive measures during the trial and for 15 weeks after the last IMP treatment
  • Subjects on extracorporeal membrane oxygenation (ECMO) at start of IMP treatment
  • Suspected hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP)

Hol van ez a vizsgálat?

9 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

To assess the efficacy of trimodulin based on 28-day all-cause mortality to demonstrate superiority to treatment with placebo

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with severe community-acquired pneumonia (sCAP)
A regiszteradat frissítve
2026. július 20.